Compare · DGX vs LH
DGX vs LH
Side-by-side comparison of Quest Diagnostics Incorporated (DGX) and Labcorp Holdings Inc. (LH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DGX and LH operate in Medical Specialities (Health Care), so they compete in similar markets.
- DGX is the larger of the two at $25.72B, about the same size as LH ($24.65B).
- Over the past year, DGX is up 27.5% and LH is up 11.8% - DGX leads by 15.7 points.
- LH has been more active in the news (10 items in the past 4 weeks vs 6 for DGX).
- Both have 25 recent analyst ratings on file.
- Company
- Quest Diagnostics Incorporated
- Labcorp Holdings Inc.
- Price
- $236.35+1.52%
- $309.00+1.62%
- Market cap
- $25.72B
- $24.65B
- 1M return
- -3.36%
- -8.50%
- 1Y return
- +27.49%
- +11.83%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 6
- 10
- Recent ratings
- 25
- 25
Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Labcorp Holdings Inc.
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Latest DGX
- Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026
- Nearly 1 in 3 Patients with Suspected Lyme Disease are Co-Positive for Other Tick-Borne Pathogens, Finds Study by Quest Diagnostics
- Nine in 10 Voters Express Concern That Medicare Lab Payment Cuts Will Harm Patient Access to Diagnostic Lab Testing, Finds National Survey from Quest Diagnostics
- Apple Health app Users to be Able to Order Labs from Quest Diagnostics
- CEO and President Davis J. E. sold $2,427,200 worth of shares (10,000 units at $242.72) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 122,423 units (SEC Form 4)
- SVP & General Counsel Prevoznik Michael E exercised 22,677 shares at a strike of $112.17, sold $5,513,083 worth of shares (22,677 units at $243.11) as part of a pre-agreed trading plan and gifted 1,000 shares, decreasing direct ownership by 3% to 36,557 units (SEC Form 4)
- Quest Diagnostics to Speak at the Baird 2026 Global Healthcare Conference
- Humanity Brings Biological Age Analysis to the U.S. Through questhealth.com
- Quest Diagnostics to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference
- Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology
Latest LH
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Labcorp Highlights Strategic Priorities Driving Durable Growth and Shareholder Value at 2026 Investor Day
- Moonwalk Biosciences Announces $70 Million Series B: NYSE Content Update
- Labcorp Acquires MLM Medical Labs, Expanding Global Central Laboratory and Biomarker Capabilities for Clinical Trials
- SEC Form 4 filed by EVP, CIO & CTO Oyegunwa Akinbolade
- SEC Form 4 filed by EVP, COO Meltzer Jonathan C
- SEC Form 4 filed by EVP and President, Diagnostics Vaughn Bryan T
- SEC Form 4 filed by EVP, Pres of BLS, CMO & CSO Caveney Brian J
- Labcorp Launches Next Generation of Labcorp Global Trial Connect™ to Help Sponsors and Investigator Sites Navigate Clinical Trial Complexity